MX343873B - Ensayo de diagnostico de anticuerpo. - Google Patents

Ensayo de diagnostico de anticuerpo.

Info

Publication number
MX343873B
MX343873B MX2013010571A MX2013010571A MX343873B MX 343873 B MX343873 B MX 343873B MX 2013010571 A MX2013010571 A MX 2013010571A MX 2013010571 A MX2013010571 A MX 2013010571A MX 343873 B MX343873 B MX 343873B
Authority
MX
Mexico
Prior art keywords
antibody assay
diagnostic antibody
diagnostic
amyloidosis
diagnosis
Prior art date
Application number
MX2013010571A
Other languages
English (en)
Other versions
MX2013010571A (es
Inventor
Kleinschmidt Martin
Schilling Stephan
Rahfeld Jens-Ulrich
Demuth Hans-Ulrich
Ebermann Kristin
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of MX2013010571A publication Critical patent/MX2013010571A/es
Publication of MX343873B publication Critical patent/MX343873B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal aislado que se enlaza a péptidos AßpGlu (11) o variantes de los mismos, en donde: dicho anticuerpo tiene un valor constante de disociación (KD) de 10-7M o menor; y la parte variable de la cadena ligera de dicho anticuerpo es codificada por una molécula de ácido nucleico que tiene la secuencia de nucleótidos de la SEQ ID NO: 51 o tiene la secuencia de aminoácidos de la SEQ ID NO: 52.
MX2013010571A 2011-03-16 2012-03-16 Ensayo de diagnostico de anticuerpo. MX343873B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453449P 2011-03-16 2011-03-16
PCT/EP2012/054629 WO2012123562A1 (en) 2011-03-16 2012-03-16 Diagnostic antibody assay

Publications (2)

Publication Number Publication Date
MX2013010571A MX2013010571A (es) 2013-12-02
MX343873B true MX343873B (es) 2016-11-25

Family

ID=45833428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010571A MX343873B (es) 2011-03-16 2012-03-16 Ensayo de diagnostico de anticuerpo.

Country Status (15)

Country Link
US (2) US8809508B2 (es)
EP (1) EP2686346B1 (es)
JP (1) JP6220675B2 (es)
KR (1) KR102020072B1 (es)
CN (1) CN103459421B (es)
AU (1) AU2012228236B2 (es)
BR (1) BR112013023211B1 (es)
CA (1) CA2828433C (es)
DK (1) DK2686346T3 (es)
EA (1) EA032054B1 (es)
IL (1) IL227847A0 (es)
MX (1) MX343873B (es)
SG (1) SG192805A1 (es)
WO (1) WO2012123562A1 (es)
ZA (1) ZA201305946B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970235B1 (en) 2013-03-15 2019-06-19 Probiodrug AG Novel inhibitors
EP3234611A1 (en) 2014-12-19 2017-10-25 Probiodrug AG Novel method for the detection of pglu-abeta peptides
IL256579B2 (en) * 2015-07-16 2023-03-01 Probiodrug Ag Human antibodies
US20210096128A1 (en) * 2019-10-01 2021-04-01 Repligen Corporation Determination of protein concentration in a fluid

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
CA2393763A1 (en) * 1999-12-08 2001-06-14 Mindset Biopharmaceuticals (Usa), Inc. Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
EP1523499A2 (en) 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
WO2008002893A2 (en) 2006-06-29 2008-01-03 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
DK2086960T3 (da) 2006-11-09 2014-06-10 Probiodrug Ag Nye inhibitorer af glutaminylcyclase.
EP2091945B1 (en) 2006-11-09 2014-01-15 Probiodrug AG Novel inhibitors of glutaminyl cyclase
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
WO2008110523A1 (en) 2007-03-09 2008-09-18 Probiodrug Ag Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase
ES2474693T3 (es) 2007-04-18 2014-07-09 Probiodrug Ag Derivados de ciano-guanidina como inhibidores de glutaminil ciclasa
WO2008128981A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US9034907B2 (en) 2007-04-18 2015-05-19 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008128986A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Urea derivatives as glutaminyl cyclase inhibitors
JP5676249B2 (ja) 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
MX2010004179A (es) * 2007-10-15 2010-08-04 Janssen Pharmaceutica Nv Anticuerpos anti-amiloide, composiciones, metodos y usos.
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
EP3338796A1 (en) * 2008-07-21 2018-06-27 Probiodrug AG Diagnostic antibody assay
WO2010128139A1 (en) * 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment
EP2448968B1 (en) * 2009-06-29 2021-01-27 BioArctic AB ANTIBODIES SELECTIVE FOR N-TERMINALTRUNCATED AMYLOID-p PROTOFIBRILS/OLIGOMERS

Also Published As

Publication number Publication date
CA2828433A1 (en) 2012-09-20
US8809508B2 (en) 2014-08-19
EP2686346A1 (en) 2014-01-22
EP2686346B1 (en) 2016-12-14
CN103459421B (zh) 2017-07-14
CA2828433C (en) 2020-08-04
AU2012228236B2 (en) 2016-10-27
SG192805A1 (en) 2013-09-30
DK2686346T3 (en) 2017-03-27
US20120237529A1 (en) 2012-09-20
KR20140006019A (ko) 2014-01-15
ZA201305946B (en) 2014-10-29
EA201301029A1 (ru) 2014-05-30
EA032054B1 (ru) 2019-04-30
KR102020072B1 (ko) 2019-11-04
AU2012228236A1 (en) 2013-10-03
MX2013010571A (es) 2013-12-02
JP2014509860A (ja) 2014-04-24
JP6220675B2 (ja) 2017-11-01
US9657089B2 (en) 2017-05-23
CN103459421A (zh) 2013-12-18
BR112013023211B1 (pt) 2022-11-08
BR112013023211A2 (pt) 2016-11-22
WO2012123562A1 (en) 2012-09-20
IL227847A0 (en) 2013-09-30
US20140255414A1 (en) 2014-09-11
NZ614217A (en) 2015-12-24

Similar Documents

Publication Publication Date Title
WO2010009987A3 (en) Diagnostic antibody assay
PH12021550083A1 (en) Human anti-tau antibodies
CY1122278T1 (el) Αντι il-36r αντισωματα
PH12015500125A1 (en) Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
AR092818A1 (es) Anticuerpo tau humanizado
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
AU2018256498A1 (en) Antibodies to amyloid beta
TN2014000120A1 (en) Cd27l antigen binding proteins
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
MA34091B1 (fr) Anticorps anti-cd40
MX345092B (es) Anticuerpos anti-tau humanos,.
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
EA201171388A1 (ru) Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида
EP2542581A4 (en) SPECIFIC APOLIPOPROTEIN ANTIBODY AND METHODS OF USING SAME
SG178886A1 (en) Humanized anti-cdcp1 antibodies
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
MX365387B (es) Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos.
WO2008136774A8 (en) Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
MX2013010571A (es) Ensayo de diagnostico de anticuerpo.
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
WO2012144784A3 (ko) 인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도
AR124605A2 (es) Anticuerpos anti-il-36r
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
TH133365A (th) แอนติ-N3pGlu อะมัยลอยด์ เบต้าเพปไทด์ แอนติบอดี และการใช้ของมัน
FR2980579B3 (fr) Procede et kit pour le diagnostic in vitro du cancer du sein

Legal Events

Date Code Title Description
FG Grant or registration